Description

This issue of Vital Signs, released on August 28, 2006, provides a strategic overview of opportunites for recombinant DNA technologies. Additionally, an emerging company profile is provided for Gerard Biotech, a leader in bringing new technologies to researchers that significantly outperform existing methods. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of August 14 - August 18, 2006.